• Prescribing Information
Login
  • My Account
  • Logout
  • Home
  • About Enhertu
    • Enhertu HER2+
      • Efficacy
      • Safety
    • Enhertu HER2 ultra-low
      • Efficacy
      • Safety
    • Enhertu HER2-low
      • Efficacy
      • Safety
    • Metastatic NSCLC
      • Efficacy
      • Safety
  • Dosing and Adverse Event Management
    • Dosing
    • Managing Adverse Event
    • Report Adverse Event
  • Support & Resources
    • Enhertu Patient Education Leaflet
    • Enhertu Patient Support Program Enrolment Form
    • Video library (Webinar)
  • Contact Us
    • Speak to our sales team
    • Speak to our medical team

Speak to our sales team
Speak to our medical team

I would like to get in touch with the Medical Team

CLICK HERE
Speak to our sales
team
Speak to our
medical team
I would like to report
an adverse event
  • Product: Enhertu HER2+
  • Product: Enhertu HER2-low
  • Dosage
  • Educational Material - Patient Start Journey
  • Webinars
  • Report an Adverse Event
  • Speak to our sales team
  • Speak to our medical team
  • Cookie Policy
© 2026 AstraZeneca.
MY-19152_March 2026

Welcome!

This website is intended to help healthcare professionals practicing in Malaysia by providing access to scientifically balanced, evidence-based, and peer-led information, and professional resources to support the evaluation of breast cancer.

The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This information is provided for educational purposes only. It is not intended for use in the diagnosis or treatment of individual patients.

I am a patient